$SNCA News
Last published 5y ago
- 5y agoSNCASeneca Biopharma Announces Successful Approval of Merger with Leading Biosciences, Inc.PR NewswireGERMANTOWN, Md., April 26, 2021 /PRNewswire/ -- Seneca Biopharma, Inc. (NASDAQ:SNCA) ("Seneca" or the "Company"), disclosed on April 23, 2021, the passing of the final proposal required for approval of the proposed merger between Seneca and Leading Bios
- 5y agoSNCALeading BioSciences Announces Early Efficacy Signal in Reducing Post-Surgical Adhesions in Open Label StudyGlobeNewswireCARLSBAD, Calif., April 20, 2021 (GLOBE NEWSWIRE) -- Leading BioSciences, Inc. ("LBS" or "the Company"), a privately held company that recently entered into a definitive agreement for a reverse merger with Seneca Biopharma, Inc. (NASDAQ:SNCA), subject
- 5y agoSNCASeneca Biopharma, Inc. Announces (i) Voting Results from the Special Meeting of Stockholders and (ii) New Special Meeting Date of April 23, 2021PR NewswireSeneca Biopharma, Inc. (Nasdaq: SNCA) ("Seneca" or the "Company"), announced the preliminary voting results of its Special Meeting of Stockholders on ...
- 5y agoSNCASeneca Announces New Special Meeting Date of April 9, 2021PR NewswireSeneca Biopharma, Inc. (Nasdaq: SNCA) (the "Company") today announced that the Company adjourned its special meeting of stockholders scheduled for...
- 5y agoSNCASeneca Biopharma Reports 2020 Yearend ResultsPR NewswireSeneca Biopharma, Inc. (Nasdaq: SNCA), a biopharmaceutical company focused on developing novel treatments for diseases of high unmet medical need,...
- 5y agoSNCAIndependent Advisory Firm ISS Recommends Seneca Biopharma, Inc. Stockholders Vote for Proposed Merger and Reverse Stock SplitPR NewswireSeneca Biopharma, Inc. (Nasdaq: SNCA), today announced that leading independent proxy advisory firm Institutional Shareholder Services, Inc. ("ISS")...
- 5y agoSNCALeading BioSciences to Present at the H.C. Wainwright Global Life Sciences ConferenceGlobeNewswireCARLSBAD, Calif., March 02, 2021 (GLOBE NEWSWIRE) -- Leading BioSciences, Inc. (“LBS”), a privately held company that recently entered into a definitive agreement for a reverse merger with Seneca...
- 5y agoSNCASeneca Biopharma Regains Compliance with NASDAQ Listing RequirementsPR NewswireSeneca Biopharma, Inc, (NASDAQ:SNCA), a biopharmaceutical company focused on developing novel treatments for diseases of high unmet medical need,...
- 5y agoSNCASeneca Biopharma, Inc. Announces Top Line Data from Phase 2 Clinical Study in China for the Treatment of Ischemic StrokePR NewswireSeneca Biopharma, Inc. (Nasdaq: SNCA), a biopharmaceutical company focused on developing novel treatments for diseases of high unmet medical need,...
- 5y agoSNCALeading BioSciences Announces FDA Fast Track Designation Granted to LB1148 for the Treatment of Postoperative Gastrointestinal Dysfunction Associated with Pediatric Cardiovascular SurgeryGlobeNewswireCARLSBAD, Calif., Jan. 13, 2021 (GLOBE NEWSWIRE) -- Leading BioSciences, Inc. (“LBS”), a privately held company that recently entered into a definitive agreement for a reverse merger with Seneca...
- 5y agoSNCAPALILeading BioSciences Announces Positive Topline Data from Open-Label Gastrointestinal Surgery StudyGlobeNewswireCARLSBAD, Calif., Jan. 08, 2021 (GLOBE NEWSWIRE) -- Leading BioSciences, Inc. (“LBS”), a privately held company that recently entered into a definitive agreement for a reverse merger with Seneca...
- 5y agoSNCALeading BioSciences and Seneca Biopharma Announce MergerPR NewswireSeneca Biopharma, Inc. (Nasdaq: SNCA) ("Seneca"), and Leading BioSciences, Inc. ("LBS"), a privately held company focused on developing novel...
- 5y agoSNCASeneca Biopharma Granted 180-Day Extension by NASDAQ to Regain Compliance with Bid Price RulePR NewswireSeneca Biopharma, Inc. (Nasdaq: SNCA), a biopharmaceutical company focused on developing novel treatments for diseases of high unmet medical need,...
- 6y agoSNCASeneca Biopharma Reports 2020 Third Quarter ResultsPR NewswireSeneca Biopharma, Inc. (Nasdaq: SNCA), a biopharmaceutical company focused on developing novel treatments for diseases of high unmet medical need,...
- 6y agoSNCASeneca Biopharma, Inc. Announces Completion of Phase II Clinical Study in China for the Treatment of Ischemic StrokePR NewswireSeneca Biopharma, Inc. (Nasdaq: SNCA), a biopharmaceutical company focused on developing novel treatments for diseases of high unmet medical need,...
- 6y agoSNCALetter from Seneca Biopharma's Executive ChairmanPR NewswireSeneca Biopharma, Inc. (Nasdaq: SNCA), a biopharmaceutical company focused on developing novel treatments for diseases of high unmet medical need,...
- 6y agoSNCASeneca Biopharma Reports 2020 Second Quarter ResultsPR NewswireSeneca Biopharma, Inc. (Nasdaq: SNCA), a biopharmaceutical company focused on developing novel treatments for diseases of high unmet medical need,...
- 6y agoSNCASeneca Biopharma, Inc. Announces Adjournment of Annual Meeting of StockholdersPR NewswireLimited to the following proposals: Proposal 3 – To ratify the filing and effectiveness of the amendment to the Company's amended and restated...
- 6y agoSNCASeneca Biopharma Announces the Closing of its $5 Million Registered Direct OfferingPR NewswireSeneca Biopharma, Inc. (Nasdaq:SNCA), a clinical-stage biopharmaceutical company developing novel treatments for various diseases of high unmet...
- 6y agoSNCASeneca Biopharma Reports Receipt of Warrant Exercise ProceedsPR NewswireSeneca Biopharma, Inc. (Nasdaq: SNCA), a biopharmaceutical company focused on developing novel treatments for diseases of high unmet medical need,...
- 6y agoSNCASeneca Biopharma Announces Pricing of $5 Million Registered Direct Offering Priced At-the-MarketPR NewswireSeneca Biopharma, Inc. (Nasdaq:SNCA), a clinical-stage biopharmaceutical company developing novel treatments for various diseases of high unmet...
- 6y agoSNCASeneca Biopharma Reports 2020 First Quarter ResultsPR NewswireSeneca Biopharma, Inc. (Nasdaq: SNCA), a biopharmaceutical company focused on developing novel treatments for diseases of high unmet medical need,...
- 6y agoSNCASeneca Biopharma Announces Results of Meeting with FDA Regarding the Design of Phase 3 Trial for NSI-566 in ALSPR NewswireSeneca Biopharma, Inc. (Nasdaq: SNCA), a clinical-stage biopharmaceutical company focused on developing novel treatments for diseases of high unmet...
- 6y agoSNCASeneca Biopharma Announces Update on Phase II Clinical Trial Underway in China for the Treatment of Ischemic StrokePR NewswireSeneca Biopharma, Inc. (Nasdaq: SNCA), a biopharmaceutical company focused on developing novel treatments for diseases of high unmet medical need,...
- 6y agoSNCASeneca Biopharma, Inc. Announces the Completion of Stem Cell Manufacturing Facility in ChinaPR NewswireSeneca Biopharma, Inc. (Nasdaq: SNCA), a biopharmaceutical company focused on developing novel treatments for diseases of high unmet medical need,...
- 6y agoSNCASeneca Biopharma Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)PR NewswireSeneca Biopharma, Inc. (Nasdaq: SNCA), a clinical-stage biopharmaceutical company developing novel treatments for diseases of high unmet medical...
- 6y agoSNCASeneca Biopharma Announces Executive Appointments and Key PromotionPR NewswireSeneca Biopharma, Inc. (Nasdaq: SNCA), a clinical-stage biopharmaceutical company developing novel treatments for diseases of high unmet medical...
- 6y agoSNCASeneca Biopharma, Inc. Reports Year End 2019 Fiscal ResultsPR NewswireSeneca Biopharma, Inc. (Nasdaq: SNCA), a biopharmaceutical company focused on developing novel treatments for diseases of high unmet medical need,...
- 6y agoSNCASeneca Biopharma Announces Closing of Exercise of Warrants for $7.55 Million Gross ProceedsPR NewswireSeneca Biopharma, Inc. (Nasdaq: SNCA), a clinical-stage biopharmaceutical company developing novel treatments for various diseases of high unmet...
- 6y agoSNCASeneca Biopharma Announces Exercise of Warrants for $7.55 Million Gross Proceeds Priced At-the-MarketPR NewswireSeneca Biopharma, Inc. (Nasdaq:SNCA), a clinical-stage biopharmaceutical company developing novel treatments for various diseases of high unmet...
- 6y agoSNCASeneca Biopharma Announces Presentations at Both Sachs Associates 3rd Annual Neuroscience Innovation Forum & Biotech Showcase™ 2020PR NewswireSeneca Biopharma, Inc., (NASDAQ: SNCA), a clinical-stage biopharmaceutical company developing novel treatments for diseases of unmet medical need,...
- 6y agoSNCASeneca Biopharma Reports Third Quarter 2019 Fiscal ResultsPR NewswireSeneca Biopharma, Inc. (Nasdaq: SNCA), a clinical-stage biopharmaceutical company developing novel treatments for various diseases of high unmet...
- 7y agoSNCASeneca Biopharma and Jiangsu QYuns Therapeutics Announce Development Plan for Potential Joint Pipeline at 7th China Renaissance Healthcare and Life Science Leadership SummitPR NewswireSeneca Biopharma, Inc., (NASDAQ: SNCA), a clinical-stage biopharmaceutical company developing novel treatments for diseases of unmet medical need,...
- 7y agoCURSNCASeneca Biopharma to Begin Trading Under New Ticker Symbol SNCAPR NewswireSeneca Biopharma, Inc., (Nasdaq: CUR), a clinical-stage biopharmaceutical company developing novel treatments for diseases of unmet medical need,...
- 7y agoCURSNCASeneca Biopharma and QYuns Therapeutics Sign Term Sheet for Global Licensing of Novel Monoclonal Antibodies for Treating Auto-Immune DiseasesPR NewswireSeneca Biopharma, Inc., (fka Neuralstem, Inc.) (NASDAQ: CUR), a clinical-stage biopharmaceutical company developing novel treatments for diseases of...